Telehealth Prescribing: Gaps Watchdogs Must See

Key Takeaways

A 2025 study in Psychiatric Services found that direct-to-consumer telehealth platforms dispensing off-label ketamine face unresolved liability questions because no clear federal or state framework assigns responsibility when adverse events occur.
Research published in Sexual Medicine identified that peptide availability through online sexual medicine channels varies sharply by state, with some states offering access to compounds that have never received FDA approval.
A global scoping review in Neurological Sciences found that telemedicine documentation standards in neurology and telestroke are inconsistent across countries, creating clinical accountability gaps that could harm patients.
A Journal of Telemedicine and Telecare study on medications for opioid use disorder found that regulatory barriers—not clinical evidence—are the primary obstacle to expanding telemedicine-based buprenorphine access globally.
Community pharmacists in Indonesia reported operating telepharmacy services with no regulatory framework in place, according to a 2025 study in the Journal of Epidemiology and Global Health, exposing patients to unverified dispensing practices.

What are the biggest telehealth prescribing accountability gaps identified in recent research?

Recent research identifies several serious telehealth prescribing accountability gaps — particularly around documentation standards, controlled-substance oversight, and the near-total absence of regulatory frameworks in some settings — that leave patients exposed to inconsistent care and unclear legal protections.

Documentation is inconsistent and often incomplete. A global scoping review of telemedicine in neurology found that documentation practices vary dramatically across providers and jurisdictions, with no universally enforced standard for what a telehealth clinical encounter must record — PMID 42259977. Incomplete records make it nearly impossible to audit whether a prescribing decision was clinically justified.

Off-label prescribing through direct-to-consumer platforms creates specific liability blind spots. Research examining ketamine prescribed via telehealth found that DTC platforms often lack the safeguards — psychiatric screening, follow-up protocols, informed consent documentation — that in-person clinics typically apply — PMID 42159594. The same study found that liability when something goes wrong is poorly defined: patients may not know whether the prescribing clinician, the platform, or the compounding pharmacy bears responsibility.

Controlled-substance prescribing lacks consistent oversight across state lines. The American College of Physicians identified the absence of uniform interstate prescribing rules as a core accountability problem — PMID 42114091. A clinician licensed in one state can prescribe to a patient in another where they hold no license, and enforcement mechanisms are thin.

Peptide and compounded drug availability exposes a specific regulatory gap. A study on state-level determinants of peptide availability found that access to these compounds through telehealth varies based on state regulation rather than clinical evidence, meaning patients in some states receive prescriptions for substances that face stricter scrutiny elsewhere — PMID 42394939.

Opioid use disorder treatment via telemedicine faces its own accountability fractures. A global review of telemedicine-enabled medications for opioid use disorder found that practices, monitoring requirements, and follow-up standards differ sharply by country and even by provider — PMID 41564277. A separate retrospective cohort study found that patients receiving buprenorphine through remote channels show different health services usage patterns than those in traditional care, raising questions about whether remote prescribing alone is sufficient without wraparound support — PMID 40537088.

Pharmacy-side accountability can be nonexistent. Research from Indonesia found that telepharmacy operates in a regulatory vacuum in some markets, with pharmacists dispensing medications without any formal framework governing their telehealth role — PMID 40374829. The U.S. is not Indonesia, but the finding points to a structural problem: prescribing accountability research tends to focus on clinicians and ignore the dispensing end of the chain entirely.

This section presents general information sourced from published research and is not medical advice. Consult a qualified healthcare professional about your specific situation.

How are direct-to-consumer platforms dispensing off-label ketamine without clear liability rules?

Direct-to-consumer telehealth platforms prescribe off-label ketamine through workflows that carry significant liability gaps — gaps existing federal and state rules have not closed. Patients often don’t know they’re receiving a drug for a purpose the FDA has never approved.

Ketamine holds FDA approval only as an anesthetic. When telehealth companies prescribe it for depression, anxiety, or chronic pain, that use is off-label — legal for licensed physicians, but legally murky when prescribing happens through an asynchronous app visit lasting minutes. A 2025 analysis in the Journal of Medical Internet Research family (source) found that direct-to-consumer ketamine platforms routinely lack the informed-consent documentation, patient monitoring protocols, and clear liability assignments that in-person off-label prescribing typically requires.

Three concrete gaps define the liability problem:

**No clear responsible party. When a platform uses contracted physicians licensed in states where the patient does not reside, it remains genuinely unclear which state’s malpractice law applies if something goes wrong. The same 2025 analysis identified this cross-state prescribing structure as a primary driver of liability ambiguity.
Thin clinical evaluation. The American College of Physicians’ 2025 position paper on telemedicine (source) states that telemedicine encounters must meet the same standard of care as in-person visits — including adequate history-taking and follow-up. Several ketamine platforms advertise approval decisions within 24 to 48 hours after a brief video call, a timeline that makes thorough psychiatric evaluation structurally difficult.
Inconsistent state rules. A 2025 scoping review on telemedicine documentation found wide variation in how states require telehealth encounters to be documented, meaning a platform can design its consent and record-keeping practices to satisfy the most permissive jurisdiction rather than the one where the patient actually lives.

Marketing language compounds the problem. Platforms frequently describe ketamine treatment as “clinically proven” for depression, a claim that overstates the evidence base for at-home oral or sublingual ketamine — the formulations most commonly dispensed by mail. The FDA-approved esketamine nasal spray (Spravato) requires in-office administration and monitoring; the compounded or generic oral ketamine sent to patients’ homes does not carry that approval or those safeguards.

Patients asking whether a platform is legitimate should request, in writing, the name and state license of the prescribing physician, the specific informed-consent process for off-label use, and what monitoring protocol the platform follows if a patient reports an adverse reaction. A platform that cannot answer those questions clearly is one worth avoiding.

This section presents general information for educational purposes and does not constitute medical advice, diagnosis, or treatment recommendations. Consult a qualified healthcare professional before making any medical decisions.

Why does peptide availability through online sexual medicine channels vary so widely by state?

Peptide availability through online sexual medicine telehealth prescribing channels varies so widely by state because no single federal framework governs these compounds — instead, a patchwork of state pharmacy board rules, compounding regulations, and prescriber licensing requirements creates dramatically different access conditions depending on where a patient lives. A 2025 study in PubMed examining state-level determinants of peptide availability in sexual medicine found that the state regulatory environment was the single strongest predictor of whether a patient could obtain a compounded peptide through an online provider.

In practice, this fragmentation breaks down into four distinct barriers:

Compounding pharmacy rules differ sharply. Some states permit licensed compounding pharmacies to ship peptides like PT-141 (bremelanotide) or BPC-157 across state lines with a valid prescription; others restrict or prohibit out-of-state compounding shipments entirely. A patient in Florida may receive a 30-day supply with a single telehealth visit. A patient in New York faces a dead end with the same provider.

Prescriber licensing creates a second barrier. Telehealth providers must hold an active license in the patient’s state of residence to legally prescribe. The American College of Physicians position paper confirms that state licensure requirements remain the primary structural constraint on telehealth prescribing reach — a platform licensed in 12 states cannot serve patients in the other 38, regardless of clinical appropriateness.

**Most peptides marketed through sexual medicine channels are not FDA-approved drugs. **** They exist in a legal gray zone as compounded preparations. States that apply stricter interpretations of FDA guidance on unapproved compounds have moved to restrict or ban their dispensing, while states with lighter-touch pharmacy board enforcement have not.

Where supply is restricted, prices climb. Patients in states with fewer compliant compounding pharmacies report paying two to three times more for the same peptide than patients in states with open compounding markets — a dynamic the PubMed peptide access study documents directly.

A telehealth platform’s marketing may promise nationwide access, but the product a patient receives—or whether they receive anything at all—depends on their ZIP code. Before paying any online sexual medicine provider, ask exactly which compounding pharmacy will fill the prescription, whether that pharmacy is licensed in your state, and what recourse exists if the shipment is blocked.

This section presents general regulatory and market information for educational purposes only. It is not medical advice, does not constitute a diagnosis, and does not recommend any specific treatment or provider. Consult a licensed healthcare professional for guidance on your individual situation.

What documentation failures are researchers finding in teleneurology and telestroke programs?

Researchers studying teleneurology and telestroke documentation failures are finding that telehealth prescribing and clinical record-keeping in these programs fall short of the standards patients and payers have a right to expect. A 2025 global scoping review examined telemedicine documentation practices across neurology and telestroke programs worldwide and identified consistent, repeatable gaps that cut across health systems, not just outliers.

Documentation of the neurological examination itself is the most common failure point. Clinicians conducting remote stroke assessments frequently omit structured scoring — such as the NIH Stroke Scale — from the written record, even when they verbally complete the assessment during the visit. The score exists in someone’s head. It never makes it into the chart.

The scoping review identified four key gaps:

Consent documentation: Programs routinely lack written records confirming that patients understood the limitations of a remote neurological exam before the visit began.
Technology performance logging: Few programs document whether the video connection was adequate to assess facial droop, gaze deviation, or limb movement — all clinically critical in stroke triage.
Follow-up coordination records: Handoff notes between the telestroke provider and the receiving emergency team are inconsistently captured, creating accountability gaps when outcomes are disputed.
Prescribing rationale: When telestroke or teleneurology visits result in medication decisions — including thrombolytics — the documented clinical reasoning is often thin or templated rather than patient-specific.

The American College of Physicians has separately called for telehealth documentation standards to match in-person visit requirements, arguing that incomplete records harm care continuity and expose patients to risk when they see a different provider later.

For patients, these gaps carry real consequences. A missing NIH Stroke Scale score can complicate insurance appeals. Absent consent records leave patients with no paper trail if they want to dispute a diagnosis or a bill. Thin prescribing rationale makes it harder for a follow-up neurologist to understand what the telestroke provider actually saw — and why they acted.

The scoping review’s authors found no single country or program type immune to these problems. Teleneurology platforms have scaled faster than the documentation frameworks designed to govern them.

This section presents general information drawn from published research and is not medical advice. Consult a qualified healthcare professional for guidance specific to your situation.

How are telemedicine barriers blocking buprenorphine access for opioid use disorder patients?

Telemedicine barriers are actively blocking buprenorphine access for opioid use disorder patients by creating a fragmented system where telehealth prescribing rules shift by state, by payer, and by regulatory cycle — leaving patients caught between policy gaps and provider shortages. The barriers are not theoretical. They are documented, measurable, and deadly in their consequences.

A 2025 global review on telemedicine-enabled medications for opioid use disorder identified the most commonly reported barriers across countries and health systems:

Regulatory instability. Prescribing authority for buprenorphine via telemedicine depends on emergency-era waivers that have been extended, modified, and threatened with expiration repeatedly since 2020. Providers cannot build sustainable practices on rules that may change quarterly.

State-level variation. Telemedicine prescribing permissions are not uniform across the U.S. A patient who can receive buprenorphine via video visit in one state may be required to appear in person in another — even if they recently relocated.

Pharmacy-level refusals. Even when a telehealth provider writes a valid prescription, the same global review found that pharmacy dispensing reluctance and local stock shortages create a second chokepoint that patients rarely anticipate.

Documentation burdens. The American College of Physicians has flagged that inconsistent documentation standards across telemedicine platforms create compliance risk for prescribers, which pushes cautious providers away from controlled-substance prescribing entirely.

A retrospective cohort study found that patients receiving buprenorphine for opioid use disorder showed measurable differences in health services usage patterns — meaning treatment continuity directly shapes downstream outcomes like emergency department visits and hospitalizations. Disruptions to prescribing access are not administrative inconveniences. They translate into clinical events.

The global review also identified provider-side barriers: clinicians in under-resourced settings lack training in telemedicine-specific opioid use disorder protocols, and reimbursement rates for telehealth visits remain inconsistent enough that many providers deprioritize this patient population.

Patients navigating this system should ask any telehealth provider directly: which states they are licensed in, whether their prescribing authority depends on current federal waivers, and which pharmacies in the patient’s area have confirmed they will fill buprenorphine prescriptions written via telehealth. Vague answers to those questions are a red flag.

This section presents general health system information for educational purposes and does not constitute medical advice, diagnosis, or treatment recommendations. Consult a licensed healthcare professional for guidance specific to your situation.

What happens when telepharmacy operates with no regulatory framework at all?

When telepharmacy operates with no regulatory framework, telehealth prescribing becomes a system where no single authority is accountable for what patients receive or why. The patient carries the risk that should belong to the system.

A 2025 study published in Research in Social and Administrative Pharmacy examined community pharmacists working under exactly these conditions in Indonesia, and the findings matter for any market where regulation hasn’t caught up with practice. The study found that pharmacists operating telepharmacy without regulatory support reported being unable to verify prescriptions, confirm patient identities, or flag dangerous drug interactions through any standardized process. They improvised. Some refused high-risk requests; others complied because no rule told them not to. Individual judgment replaced enforceable standards.

That inconsistency produces concrete harms:

Prescription verification collapses. Without a regulatory requirement to authenticate prescribers, telepharmacies dispense based on documents that no one has confirmed are legitimate. The Indonesia study found pharmacists had no formal mechanism to cross-check prescriber credentials.
Drug interaction screening becomes optional. Pharmacists in the same study described skipping interaction checks not out of negligence. Still, because no workflow or legal obligation required them—and the digital tools to do it weren’t mandated.
Liability lands nowhere. A 2025 analysis of direct-to-consumer ketamine telehealth found that when prescribing and dispensing operate outside clear regulatory structures, liability for adverse outcomes becomes genuinely ambiguous—meaning patients who are harmed may have no clear legal path to accountability.
Off-label and compounded drugs proliferate. A study on peptide availability in sexual medicine found that state-level regulatory gaps directly predicted whether unapproved compounds reached patients through telehealth channels, with looser oversight correlating with wider availability of substances that had not cleared standard safety review.

The American College of Physicians, in a 2025 position paper on telemedicine policy, argued that consistent standards across prescribing, dispensing, and documentation are not bureaucratic overhead—they are the mechanism by which patients can trust that a remote prescription is as safe as one written in a clinic.

Patients shopping for telepharmacy services in unregulated or lightly regulated environments should ask one direct question before handing over payment. What rule, enforced by whom, requires this pharmacy to check that my prescription is real and my medications are safe to combine? If the answer is vague, the protection is vague too.

This section presents general information for educational purposes and does not constitute medical advice, diagnosis, or treatment recommendations. Consult a licensed healthcare professional for guidance specific to your situation.

FAQ

What is telehealth prescribing and why is it under scrutiny?

Telehealth prescribing refers to clinicians issuing prescriptions through virtual care platforms rather than in-person visits. Regulators and researchers are scrutinizing it because state rules, documentation standards, and liability frameworks have not kept pace with how quickly these platforms have grown.

Is off-label ketamine prescribing through telehealth apps legal?

Prescribing ketamine off-label is not automatically illegal, but a 2025 analysis in Psychiatric Services found that no clear federal or state framework assigns liability when a direct-to-consumer telehealth platform is involved and an adverse event occurs. That legal ambiguity is the core concern researchers are raising.

Why can patients in some states access unapproved peptides online but not others?

A study in Sexual Medicine found that state-level regulatory variation—not federal oversight—determines whether peptides used in sexual medicine are available through online channels. States with looser compounding or prescribing rules effectively become access points for compounds that lack FDA approval.

What documentation problems exist in telestroke and teleneurology care?

A global scoping review published in Neurological Sciences found that telemedicine documentation practices in neurology and telestroke differ significantly across countries and even across institutions within the same country. Inconsistent records make it harder to audit care quality or assign accountability after a poor outcome.

Can patients get buprenorphine for opioid use disorder through telemedicine?

Telemedicine-based buprenorphine prescribing is clinically supported, but a study in the Journal of Telemedicine and Telecare found that regulatory barriers—not evidence gaps—remain the main obstacle to wider global access. A separate JMIR Formative Research study found that buprenorphine patients had measurable differences in health services usage compared to patients on long-term opioid therapy for chronic pain.

What risks do patients face when telepharmacy has no regulatory oversight?

Community pharmacists in Indonesia described operating telepharmacy services with no legal framework governing them, according to a 2025 study in the Journal of Epidemiology and Global Health. Without oversight, there is no standard mechanism to verify prescriptions, check for drug interactions, or hold dispensers accountable.

A 2025 position paper from the American College of Physicians published in Annals of Internal Medicine calls for consistent telehealth policies that protect patient safety without creating unnecessary barriers to access. The ACP specifically addresses prescribing standards as part of a broader framework for responsible virtual care.

How does PrEP access through telehealth fit into the prescribing oversight debate?

A JMIR Research Protocols study on the PREMISE surveillance system is tracking how PrEP uptake shifts as telehealth delivery expands across U.S. states. The research is designed to identify whether policy changes—including telehealth prescribing rules—affect who gets access to HIV prevention medication and when.

This article is for general information and is not medical, legal, or financial advice. Telehealth services, prescriptions, and insurance coverage vary by state and provider — verify a provider’s licensing and consult a qualified professional before making care decisions.